-
Sector Analysis
NewAntibody-Drug Conjugates (ADC) Overview, Industry Trends, Marketed and Pipeline Products, Opportunities and Challenges
Antibody-Drug Conjugates Market Report Overview An Antibody-Drug Conjugates (ADC) drug consists of monoclonal antibodies conjugated to a payload via a linker, for the precise targeting of antigen-positive cancer cells. ADCs are developed to target protein receptors with high expression such as HER2, TROP-2, CD22, and others. There are two cytotoxic payload types predominantly used in ADCs including microtubule inhibitors, and the more potent DNA-damaging payloads such as topoisomerase I inhibitors. The ADC market research report will aid clients in gaining...
-
Innovation Ranking
NewInnovation Ranking – AstraZeneca Plc
AstraZeneca Plc (AstraZeneca) is a biopharmaceutical company, which is focused on discovery, production and commercialization of a range of prescription drugs. It develops products related to therapy areas such as respiratory, cardiovascular, renal and metabolic diseases, cancer, autoimmune, infection and neurological diseases. The company’s product portfolio includes biologics, prescription pharmaceuticals and vaccines. AstraZeneca sells its products through wholly- owned local marketing companies, distributors and local representative offices. The company markets its products to primary care and specialty care physicians. The...
-
Product Insights
NewBorderline Personality Disorder (BPD) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Borderline Personality Disorder (BPD) Clinical Trial Report Overview A total of 71 borderline personality disorder (BPD) clinical trials were conducted as of March 2024. The borderline personality disorder (BPD) clinical trial report provides a comprehensive understanding of the borderline personality disorder (BPD) clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor types and the prominent sponsors associated with...
-
Product Insights
NewBronchiectasis Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Bronchiectasis Clinical Trial Report Overview A total of 394 Bronchiectasis clinical trials were conducted as of March 2024. The Bronchiectasis clinical trial report provides a comprehensive understanding of the Bronchiectasis clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor types and the prominent sponsors associated with the trials. Key Regions ·       Asia-Pacific ·       Europe ·       North America ·       ...
-
Product Insights
NewObsessive-Compulsive Disorder Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Obsessive-Compulsive Disorder Clinical Trial Market Report Overview Obsessive-compulsive disorder clinical trial market research report provides top line data relating to the clinical trials on obsessive-compulsive disorder. The report includes an overview of trials count and their average enrollment in top countries conducted globally. The report includes coverage of disease clinical trials by region and top countries, trial phase, trial status, end points status and sponsor type. The report also provides prominent drug names and trial counts for in-progress trials. Key...
-
Product Insights
NewNet Present Value Model: AstraZeneca Plc’s Zibotentan/Forxiga
Empower your strategies with our Net Present Value Model: AstraZeneca Plc's Zibotentan/Forxiga report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: AstraZeneca Plc’s Datopotamab Deruxtecan
Empower your strategies with our Net Present Value Model: AstraZeneca Plc's Datopotamab Deruxtecan report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: F. Hoffmann-La Roche Ltd’s Inavolisib
Empower your strategies with our Net Present Value Model: F. Hoffmann-La Roche Ltd's Inavolisib report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: AstraZeneca Plc’s Camizestrant
Empower your strategies with our Net Present Value Model: AstraZeneca Plc's Camizestrant report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.